...
首页> 外文期刊>Virology >RECOMBINANT HUMAN IMMUNODEFICIENCY PR55(GAG) VIRUS-LIKE PARTICLES PRESENTING CHIMERIC ENVELOPE GLYCOPROTEINS INDUCE CYTOTOXIC T-CELLS AND NEUTRALIZING ANTIBODIES
【24h】

RECOMBINANT HUMAN IMMUNODEFICIENCY PR55(GAG) VIRUS-LIKE PARTICLES PRESENTING CHIMERIC ENVELOPE GLYCOPROTEINS INDUCE CYTOTOXIC T-CELLS AND NEUTRALIZING ANTIBODIES

机译:重组人免疫功能低下的PR55(GAG)病毒样颗粒,用于嵌合包膜糖蛋白诱导细胞毒性T细胞和中和抗体

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Very recently, we demonstrated that the replacement of the human immunodeficiency virus type-1 (HIV-1) gp41 transmembrane protein by an Epstein-Barr virus gp220/350-derived membrane anchor resulted in the incorporation of chimeric envelope (Env) oligomers into pr55(gag) virus-like particles (VLPs), exceeding that of wild-type gp160 by a factor of 10, In this study, we examined the immunostimulatory properties of Pr55(gag) VLPs to both (i) chimeric HIV-1 gp120 external envelope proteins and (ii) full-length gp160 presented on the outer surface of the particles. immunization studies carried out with VLPs presenting different derivatives of the chimeric and wild-type Enu proteins elicited a consistent anti-Pr55(gag) as well as anti-Env antibody response in complete absence of additional adjuvants. In both cases, the immune sera exhibited an in vitro neutralizing activity against homologous HIV-1 infection in MT4 cells, Noteworthy, these VLPs were also capable of inducing a strong CD8+ cytotoxic T-cell (CTL) response in immunized BALB/c mice that was directed toward a known CTL epitope in the third variable domain V3 of the gp120 external glycoprotein. However, the induction of V3-loop-specific CTLs critically depended on the amounts of Env proteins that were presented by the Pr55(gag) VLPs. Moreover, the CD8(+) CTL response was not significantly altered by adsorbing the VLPs to alum or by repeated boaster immunizations. These results illustrate that Pr55(gag) VLPS provide a safe and effective means of enhancing neutralizing humoral responses to particle-entrapped gp120 proteins and are also capable of delivering these proteins to the MHC class i antigen processing and presentation pathway. Therefore, antigenically expanded Pr55(gag) VLPS represent an attractive approach in the design of vaccines for which specific stimulation of neutralizing antibodies and cytotoxic effector functions to complex glycoproteins is desired.
机译:最近,我们证明了由爱泼斯坦-巴尔病毒gp220 / 350衍生的膜锚蛋白替代人类1型免疫缺陷病毒(HIV-1)gp41跨膜蛋白导致嵌合包膜(Env)低聚物掺入pr55 (gag)病毒样颗粒(VLP),超过野生型gp160的10倍。在这项研究中,我们研究了Pr55(gag)VLP对两种(i)嵌合HIV-1 gp120外部的免疫刺激特性包膜蛋白和(ii)出现在颗粒外表面的全长gp160。在完全不存在其他佐剂的情况下,用呈现嵌合和野生型Enu蛋白不同衍生物的VLP进行的免疫研究引发了一致的抗Pr55(gag)和抗Env抗体反应。在这两种情况下,免疫血清均对MT4细胞中的同源HIV-1感染具有体外中和活性,值得注意的是,这些VLP还能在免疫BALB / c小鼠中诱导强烈的CD8 +细胞毒性T细胞(CTL)反应,定向于gp120外部糖蛋白的第三可变结构域V3中的已知CTL表位。但是,V3回路特定CTL的诱导关键取决于Pr55(gag)VLP呈现的Env蛋白的量。此外,通过将VLP吸附到明矾上或通过反复的免疫接种,CD8(+)CTL反应没有显着改变。这些结果表明,Pr55(gag)VLPS提供了一种安全有效的方法,可以增强对颗粒捕获的gp120蛋白的中和体液反应,并且还能够将这些蛋白传递至MHC I类抗原加工和呈递途径。因此,抗原扩增的Pr55(gag)VLPS代表了一种诱人的疫苗设计方法,为此,需要特异性刺激中和抗体和对复杂糖蛋白的细胞毒效应子功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号